Dr Reddy's plans to spend us$ 400 million on R&D

The drug firm plans to focus on biologics and proprietary products over 3-4 years.


New Delhi, April 11, 2014: Dr Reddy’s Laboratories plans to invest close to US$ 400 million on R&D over the next 3-4 years. The investment will focus on biologics and proprietary products as the company expects a wave of big growth in this segment.


It may be noted here that the company has 21 active products in proprietary products pipeline, out of which close to six were in the clinical development phase as on March 31, 2013.


The company has said that the future R&D focus of the company would be on the two segments and it expects biologics and proprietary products to contribute significantly to its top line after a period of five years.


* Indicates mandatory field.
Please wait while comments are being sent...